Search results for "Tipa"

2. tipa cukura diabēta pacientu individualizēta terapija un tās nozīmēšanas kritēriji atbilstoši fenotipam

2015

2.tipa cukura diabēts ir hroniska slimība,kuras izplatība strauji pieaug visā pasaulē.Neraugoties uz izstrādātām vadlīnijām ārstiem,kā sākt2.tipaCD ārstēšanu,ne visi pacienti sasniedz mērķa glikēmiju un glikēta hemoglobīna(HbA1c)līmeni.Izpētīti228akūti hospitalizēti 2.tipaCD pacienti,kuri ārstējās no2013.gada janvāra līdz2014.gada septembrim.Liela uzmanība pievērsta pacientu bioķīmiskajiem radītājiem:triglicerīdi(TG), c-peptīds,HbA1c,GFĀ,ĶMI,ārstam,kas ārstēja noteiktu pacientu,terapijas izvēlei,pacientam izrakstoties no stacionāra. Fenotipiski pacienti sadalīti četrās grupās.Pirmajā grupā bija73pacienti ar hronisku nieru slimību(GFĀ30 kg/m2),66cilvēki bija vecāka gadagājuma pacientu grupā(…

Visa genoma asociācijas pētījumā identificēti četri riska polimorfismi un izveidots poligēnā riska modelis 2. tipa diabēta pacientiem Latvijas populā…

2020

Maģistra darbs veltīts 2. tipa cukura diabēta ģenētisko cēloņu izpētei Latvijas populācijā, kā arī automatizētas visa genoma asociācijas pētījumu darbplūsmas programmas izveidei. Darba ietvaros noskaidroti četri Latvijā bieži sastopami viena nukleotīda polimorfismi, kas būtiski asociēti ar 2. tipa cukura diabēta risku. Trīs no tiem atrodas gēnos LOC105370658, STK39 un BTNL2, kas ekspresējas un ir nozīmīgi aizkuņģa dziedzera insulīnu sekretējošo beta šūnu darbībā. Apvienojot 41 polimorfismu poligēnā riska modelī (PRS), izskaidroti 11% no slimības variācijas ar AUC 0.69. Cilvēkiem ar augstāko noteikto PRS ir 2.8 reizes palielināts 2. tipa diabēta risks, salīdzinot ar vidējo. Papildus tam, Lat…

2. tipa cukura diabēta ārstēšanai paredzēto medikamentu aprite aptiekā un ar to lietošanu saistītās blakusparādības

2020

2. tipa cukura diabēts ir viena no izplatītākajām slimībām pasaulē, izraisot mikrovaskulāras un makrovaskulāras komplikācijas. Slimība ir hroniska un progresē pēc 45 gadu vecuma saistībā ar nepilnvērtīgu uzturu un mazkustīgu dzīvesveidu. Katru gadu 2. tipa cukura diabēta pacientu skaits pieaug un līdz ar to arī antidiabētisko līdzekļu patēriņš. Darba mērķis bija izpētīt 2. tipa cukura diabēta ārstēšanai paredzēto medikamentu apriti aptiekā un ar antidiabētisko medikamentu lietošanu saistītās blakusparādības. Pētījuma rezultāti liecina, ka 2. tipa cukura diabēta ārstēšanai vairāk tiek izrakstīti perorālie antidiabētiskie medikamenti, no kuriem populārākā antidiabētisko medikamentu grupas zāļ…

Latvijas Universitātes Raksti. 755. sēj.

2010

Large numbers of cold positronium atoms created in laser-selected Rydberg states using resonant charge exchange

2016

Lasers are used to control the production of highly excited positronium atoms (Ps*). The laser light excites Cs atoms to Rydberg states that have a large cross section for resonant charge-exchange collisions with cold trapped positrons. For each trial with 30 million trapped positrons, more than 700 000 of the created Ps* have trajectories near the axis of the apparatus, and are detected using Stark ionization. This number of Ps* is 500 times higher than realized in an earlier proof-of-principle demonstration (2004 Phys. Lett. B 597 257). A second charge exchange of these near-axis Ps* with trapped antiprotons could be used to produce cold antihydrogen, and this antihydrogen production is e…

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive an…

2019

Background:Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient population.Methods:In this open-label phase IIIb study, patients with moderate-to-severe IBS-C received linaclotide 290 μg once daily for 12 weeks. The primary endpoint was clinical response at week 12, defined as >30% reduction in IBS symptom severity score (IBS-SSS) or IBS-SSS <75 plus self-reported response of feeling ‘better’ or ‘much better’ versus the baseline. Digestive nonintestinal an…

New prospective in treatment of Parkinson's disease: Studies on permeation of ropinirole through buccal mucosa

2012

The aptitude of ropinirole to permeate the buccal tissue was tested using porcine mucosa mounted on Franz-type diffusion cells as ex vivo model. Drug permeation was also evaluated in presence of various penetration enhancers and in iontophoretic conditions. Ropinirole, widely used in treatment of motor fluctuations of Parkinson's disease, passes the buccal mucosa. Flux and permeability coefficient values suggested that the membrane does not appear a limiting step to the drug absorption. Nevertheless, an initial lag time is observed but the input rate can be modulated by permeation enhancement using limonene or by application of electric fields. Absorption improvement was accompanied by the …

Effect of lactose, lactulose and bisacodyl on gastrointestinal transit studied by metal detector.

2007

SUMMARY Aim and methods: To study the effect of 45 g lactose, 30 g lactulose and 10 mg bisacodyl on gastrointestinal transit in 30 healthy volunteers by metal detector and Hinton marker method. The first set of measurements were performed under standard conditions. In a second stage, transit was slowed to twice the original value by loperamide to simulate constipation conditions. Results: Bisacodyl drastically accelerated small and large intestinal transit. Colonic transit was shortened to 23 % and to 31% of control values, without and with loperamide. Bisacodyl increased stool weight and decreased stool consistency in all persons. Lactulose marginally shortened small intestinal transit (P=…

Gallstone dissolution with chenodeoxycholic acid. A clinical study.

1980

Out of 95 patients with radiolucent gallstones who enrolled in a clinical study with chenodeoxycholic acid (CDC) for gallstone dissolution 75 patients with cholecystolithiasis completed 12 months of treatment. As a side effect 31% of patients reported intermittent diarrhea which did not cause cessation of therapy or missing of work. The incidence of biliary colic was markedly decreased during treatment in comparison to the rate in the year before. From more than 20 laboratory values checked before start and every 3 months during therapy only aminotransferases increased up to 3 fold in 20% of patients. gamma-GT elevated in 31% of patients before treatment improved in half of these patients d…

Influence of Senna, Fibre, and Fibre + Senna on Colonic Transit in Loperamide-induced Constipation

1993

Retarded colonic transit and disturbed defecation are the most prominent pathophysiological mechanisms in constipation. Both may be influenced by bulking agents and by laxatives such as senna. Direct measurements of the influence of such substances on colonic transit are rare mainly because of technical problems. We measured gastric emptying, small and large intestinal transit in 24 healthy volunteers by a newly developed method employing a metal detector. Twelve persons taking a normal diet received loperamide in a dose sufficient to double the individual transit time. All subjects measured gastrointestinal transit time under normal conditions and with Sennatin containing purified sennosid…